*Department of Pathology, Laboratory Medicine Program, University Health Network
†Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON
Departments of ‡Community Health and Epidemiology
¶Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan and Saskatchewan Health Authority, Saskatoon, SK
§Canadian Immunohistochemistry Quality Control
∥Department of Pathology, Vancouver General Hospital, University of British Columbia, Vancouver, BC
C.C.C.: has been a consultant for and/or received grant support from Agilent, Astra-Zeneca, Bristol-Myers-Squibb, Cell Marque/Sigma, MSD, and Roche outside of the submitted work. E.E.T.: has been a consultant for and/or received grant support from Astra-Zeneca, Bristol-Myers-Squibb, Cell Marque/Sigma, Janssen, MSD, Pfizer, and Roche outside of the submitted work. The remaining authors declare that they have nothing to disclose.
Reprints: Emina E. Torlakovic, MD, PhD, Department of Pathology and Laboratory Medicine, Royal University Hospital, 103 Hospital Drive, Saskatoon, SK, Canada S7N 0W8 (e-mail: [email protected]).
